Yuhan Corporation
↗Seoul, South Korea
Yuhan Corporation is a major South Korean pharmaceutical and chemical company founded in 1926. It operates as an integrated healthcare company with business segments spanning primary and specialty care, dietary supplements, household and animal care, and contract manufacturing (CDMO) of active pharmaceutical ingredients (APIs).
In recent years, Yuhan has significantly expanded its R&D focus on innovative new drug development, particularly in oncology, immunology, and metabolic diseases. The company has gained international recognition for its lung cancer drug, Leclaza (lazertinib), which has achieved global regulatory approvals and strategic partnerships with multinational pharmaceutical companies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$1.54B
Founded:1926
Ownership:public
Status:operating
STOCK
Exchange:KRX
Ticker:000100
Market Cap:$5.02B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (Leclaza/Lazertinib)
Modalities:Small molecule, Targeted therapy, Immunotherapy
Active Trials:0
Trial Phases:-
FDA Approvals:1
EMA Approvals:1
CORPORATE STRUCTURE
Subsidiaries:Yuhan USA Corporation, Yuhan Chemical, Inc., Yuhan-Kimberly
Key Partnerships:Janssen Biotech (Leclaza collaboration), Gilead Sciences (API supply), Boehringer Ingelheim (past collaboration)
COMPETITION
Position:Leader
Competitors:Celltrion, Samsung Biologics, GC Pharma, Hanmi Pharmaceutical
LEADERSHIP
Key Executives:
Cho Wook-je - CEO
Kim Yeol-hong - President of R&D
LINKS
Website:yuhan.co.kr
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Yuhan Corporation and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Yuhan Corporation. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.